Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2002-08-13
2009-12-01
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S009810, C424S093710, C435S002000, C604S004010, C604S006030, C604S006080
Reexamination Certificate
active
07625557
ABSTRACT:
Transimmunization methods incorporating skin immunologic challenges are described for either selectively suppressing the immune response of recipients of transplanted tissue or cells or monitoring induced anti-cancer immunity. In one embodiment, skin from the transplant donor is allografted to the transplant recipient to induce an immunological response to the transplanted skin. A quantity of blood is taken from the recipient and treated to render the T cells in the blood apoptotic and to induce differentiation of blood monocytes into dendritic cells. The treated blood is incubated and administered to the recipient to induce formation of suppressor T cell clones which reduce the number of T cells attacking the transplanted tissue or organ. This tolerogenic approach can be complemented by also feeding the immature dendritic cells apoptotic or necrotic cells from the organ donor. In a second embodiment, dendritic cells loaded with tumor antigens are injected intradermally to monitor the anti-cancer immunity induced by Transimmunization.
REFERENCES:
patent: 4321918 (1982-03-01), Clark, II
patent: 4683889 (1987-08-01), Edelson
patent: 4838852 (1989-06-01), Edelson et al.
patent: 6194204 (2001-02-01), Crawford et al.
patent: 6524855 (2003-02-01), Edelson et al.
patent: 6596275 (2003-07-01), Bartholeyns et al.
patent: 6602709 (2003-08-01), Albert et al.
patent: 6800300 (2004-10-01), Miller et al.
patent: 2002/0051771 (2002-05-01), Bolton et al.
patent: 2002/0114793 (2002-08-01), Edelson et al.
patent: 2003/0133914 (2003-07-01), Edelson et al.
patent: 2005/0084966 (2005-04-01), Edelson et al.
patent: WO 97/34472 (1997-09-01), None
patent: WO 00/62818 (2000-10-01), None
Greinix, et al. Successful Use of Extracorporeal Photochemotherapy in the Treatment of Severe Acute and Chronic Graft-Versus-Host Disease, Blood, vol. 92, No. 9, 1998, pp. 3098-3104.
Greinix, et al. Extracorporeal Photochemotherapy in the Treatment of Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Pilot Study, Blood, vol. 96, No. 7,, 2000, pp. 2426-2431.
Barr, et al. Photopheresis for the Prevention of Rejection in Cardiac Transplantation, The New England Journal of Medicine, 1998, pp. 1744-1751.
Yamane, et al. Suppression of Anti-Skin-Allograft Response by Photodamaged Effector Cells-The Modulating Effects of Prednisolone and Cyclophosphamide, Transplantation, 1992, pp. 119-124.
Perez, Induction of a Cell-Transferable Suppression of Alloreactivity by Photodamaged Lymphocytes, Transplantation, 1992, pp. 896-903.
Perez, DNA Associated with the Cell Membrane is Involved in the Inhibition of the Skin Rejection Response in the Inhibition of the Skin Rejection Response Induced by Infusions of Photodamaged Alloreactive Cells that Mediate Rejection of Skin Allograft, Photochemistry and Photobiology, vol. 55, No. 6, 1992, pp. 839-849.
Russell-Jones, R. Shedding Light on Photophersis. The Lancet. Mar. 17, 2001, vol. 357, pp. 820-821.
PCT/US02/25703 International Preliminary Examination Report Dated May 10, 2005.
Fay, et al., Dendritic cell immunotherapy of metastatic melanoma using CD34+ hemotopietic progenitor-derived dendritic cells (CD34-DC) induced immune responses to melanoma antigen and resulted in clinical regression of metastatic disease, Blood, Nov. 16, 2000, vol. 96, p. 807a.
Oliven et al: “Extracorporeal Photopheresis: a review”, Blood Reviews, vol. 15, Jun. 2001, pp. 103-108.
Rook et al: Photopheresis: Clinical application and Mechanism of Actions:, Journal of Investigative Dermatology Symposium Proceedings, vol. 4, nr. 1, Sep. 1999 pp. 85-90.
Kanada et al: “Photopheresis Monocytes Produce Cytokines that Induce Monocyte-to-Dendritic Cell Maturation During Overnight Incubation”, Journal of Investigative Dermatology, vol. 117, nr. 2, May 12, 2001 p. 535, abstract 873.
Berger et al: “Induction of Tumor-Loaded Dendritic Cells”, Int J Cancer, vol. 91, Feb. 15, 2001, pp. 438-447.
European Communication dated Dec. 22, 2006 for application no. 02 750 482.6-1222.
Brooks, CG. “The effects of cell density, incubation temperature, syngeneic serum, and syngeneic red blood cells on mouse lymphocyte responses in vitro”, J Immunol Methods, Dec. 9, 1975 (2): 171-84, abstract.
Purrott, R.J. et al.; Cellular and Molecular Life Sciences; vol. 37, No. 4, Apr. 1981; pp. 407-408; abstract.
Cohen, et al. CD4+CD25+ Immunoregulatory T Cells: New Therapeutics for Graft-Versus-Host Disease, The Rockefeller University Press, vol. 196, No. 3, Aug. 5, 2002, pp. 401-406.
Chambers, The expanding world of co-stimulation: the two-signal model revised, Trends in Immunology, vol. 22, No. 4, Apr. 2001, pp. 217-223.
Hoffmann, et al. Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation, The Rockefeller University Press, vol. 196, No. 3, Aug. 5, 2002, pp. 389-399.
Rossi, M. et al., Plasmacytoid Dendritic Cells: Do They Have a Role in Immune Responses After Hematopoietic Cell Transplantation? Human Immunology Dec. 2002, vol. 63, No. 12, pp. 1194-1200.
Heshmati, F. Mechanisms of Action of Extracorporeal Photochemotherapy Transfusion and Apheresis Science Aug. 2003, vol. 29, No. 1, pp. 61-70, Abstract.
Ying G et al: “Tricyclic antidepressants prevent the differentiation of monocytes into macrophage-like cells in vitro.” Cel Biol Toxicol 2002; 18(6):425-37, Abstr. Only.
Beaudoin L et al: “NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells.” Immunity. Dec. 2002; 17(6):725-36, Abstr. Only.
Kitazawa T et al: “Studies on delayed systemic effects of ultraviolet B radiation on the induction of contact hypersensitivity, 3. Dendritic cells from secondary lymphoid organs are deficient in interleukin-12 production and capacity to promote activation and differentiation of T helper type 1 cells.” Immunology. Feb. 2000;99(2):296-304, Abstr. Only.
Tang A et al: “Inhibition of epidermal Langerhans cell function by low dose ultraviolet B radiation. Ultraviolet B radiation selectively modulates ICAM-1 (CD54) expression by murine Langerhans cells.” J Immunol. May 15, 1991;146(10):3347-55, Abstr. Only.
Shen W et al: “Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells.” Cell Immunol. Dec. 2002;220(2):125-33, Abstr. Only.
Lateef Z et al: “Orf virus-encoded interleukin-10 inhibits maturation, antigen presentation and migration of murine dendritic cells.” J Gen Virol. May 2003;84(Pt5): 1101-9, Abstr. Only.
Shurin MR et al: “Inhibition of CD40 expression and CD-40-mediated dentritic dell function by tumor-derived IL-10.” Int J Cancer. Sep. 1, 2002;101(1):61-8, Abstr. Only.
Semnani RT et al: “Filarial antigens impair the function of human dendritic cells during differentiation.” Infect Immun. Sep. 2001;69(9):5313-22, Abstr. Only.
Chung F: “Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma.” Mediators Inflamm. Apr. 2001;10(2):51-9. Links, Abstr. Only.
Hackstein H et al: “Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dentritic cells.” J Immunol. Jun. 15, 2001;166(12):7053-62, Abstr. Only.
Komi J et al: “Non-steroidal anti-oestrogens inhibit the differentiation of synovial macrophages into dendritic cells.” Rheumatology (Oxford). Feb. 2001;40(2):185-91, Abstr. Only.
Moore KW et al: “Interleukin-10 and the interleukin-10 receptor.” Annu Rev Immunol. 2001;19:683-765, Abstr. Only.
Bernstein SH et al: “A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1 alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.” BR J Haematol. Dec. 1997;99(4):888-95, Abstr. Only.
Askenase PW et al: “Gamma delta T cells in normal spleen assist immunized alpha beta T cells in t
McCarter & English LLP
Saunders David A
Yale University
LandOfFree
Method for inducing selectively suppressed immune response... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inducing selectively suppressed immune response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inducing selectively suppressed immune response... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4053376